A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1601 details |
| Primary information | |
|---|---|
| ThPP ID | Th1127 |
| Therapeutic Peptide/Protein Name | Buserelin |
| Sequence | pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt view full sequnce in fasta |
| Functional Classification | IIIc |
| Molecular Weight | N.A. |
| Chemical Formula | C62H90N16O15 |
| Isoelectric Point | N.A. |
| Hydrophobicity | N.A. |
| Melting Point (℃) | N.A. |
| Half Life | 50-80 minutes by IV dose, 80 mins. By SC dose, 1-2 hrs by Intranasal dose |
| Description | Buserelin is a luteinizing hormone-releasing hormone (LHRH) agonist. It is a synthetic hormone which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR) and is used in prostate cancer treatment. |
| Indication/Disease | Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. |
| Pharmacodynamics | N.A. |
| Mechanism of Action | Buserelin stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). Buserelin desensitizes the GnRH receptor, reducing the amount of LH and testosterone. However, there is a concomitant surge in LH and testosterone levels with the decrease in androgens, so antiandrogens must administered. |
| Toxicity | N.A. |
| Metabolism | N.A. |
| Absorption | N.A. |
| Volume of Distribution | N.A. |
| Clearance | N.A. |
| Categories | N.A. |
| Patents Number | N.A. |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | N.A. |
| Target | N.A. |
| Information of corresponding available drug in the market | |
| Brand Name | Suprecur (injection) |
| Company | Sanofi-Aventis |
| Brand Discription | Suprecur 1mg/ml Injection (called Suprecur Injection throughout this leaflet). It contains a medicine called buserelin acetate. This belongs to a group of medicines called gonadotropin releasing hormone analogues. This is a synthetic version of a hormone that occurs naturally in the body. It works by lowering the production of sex hormones. It can be used to treat infertility. It works by stopping the natural production of hormones that control ovulation. Synthetic hormones are then used to artificially stimulate ovulation. Your doctor should give you more information about how your treatment works. |
| Prescribed for | infertility |
| Chemical Name | N.A. |
| Formulation | Each 1ml of solution contains 1 milligram of the active substance, buserelin as buserelin acetate. The other ingredients are, sodium chloride, sodium dihydrogen phosphate, sodium hydroxide, benzyl alcohol and water for injections |
| Physcial Appearnce | 1mg/ml Injection |
| Route of Administration | Subcutaneous |
| Recommended Dosage | Treatment starts on day 1 or day 21 of menstrual cycle. Daily dose is: 200 to 500 micrograms given as a single daily injection or 500 micrograms twice a day; Daily injections until blood tests show that levels of sex hormones are lowered. This usually takes one to three weeks; After this other hormones along with Suprecur Injection;Doctor determines the treatment time |
| Contraindication | Do not have this medicine and tell your doctor if: Allergy (hypersensitive) to buserelin or other similar medicines such as goserelin, or any of the other ingredients of Suprecur Injection. Abnormal menstrual bleeding Pregnancy or breast-feeding A tumour that is not affected by changes in hormone levels. This medicine is for use in women only. However there is another form of this medicine that can be used in men. Men should not use either form of this medicine if they have had their testicles removed. |
| Side Effects | N.A. |
| Useful Link | http://www.drugs.com/uk/pdf/leaflet/468557.pdf |
| PubMed ID | 25496312, 25293536, 25276180, 24690459, 24657556 |
| 3-D Structure | N.A. |